Shares of CryoLife, Inc. (NYSE:CRY) reached a new 52-week high during trading on Tuesday . The company traded as high as $22.15 and last traded at $22.15, with a volume of 154,571 shares. The stock had previously closed at $21.50.

CRY has been the subject of a number of research analyst reports. Zacks Investment Research upgraded CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $22.00.

The stock has a market capitalization of $734.14 million, a price-to-earnings ratio of 66.52 and a beta of 0.97. The company has a 50 day moving average price of $19.31 and a 200-day moving average price of $18.10.

CryoLife (NYSE:CRY) last announced its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 EPS. Analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

In other CryoLife news, VP Amy Horton sold 9,577 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total value of $191,540.00. Following the sale, the vice president now directly owns 112,282 shares in the company, valued at approximately $2,245,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 125,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the completion of the sale, the chief executive officer now owns 398,399 shares in the company, valued at $8,768,761.99. The disclosure for this sale can be found here. Insiders sold a total of 178,627 shares of company stock worth $3,915,765 in the last quarter. Insiders own 6.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue grew its position in CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 2,407 shares during the last quarter. First Mercantile Trust Co. grew its position in CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 291 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its position in CryoLife by 3.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 190 shares during the last quarter. Mason Street Advisors LLC grew its position in CryoLife by 7.4% in the 1st quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 438 shares during the last quarter. Finally, Creative Planning grew its position in CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 68.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CryoLife, Inc. (CRY) Sets New 1-Year High at $22.15” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/06/cryolife-inc-cry-sets-new-1-year-high-at-22-15.html.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.